BIM
IDXG

BlackRock Investment Management’s Interpace Biosciences, Inc. Common Stock IDXG Stock Holding History

BlackRock Investment Management’s Portfolio IDXG Stock Details IDXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-18
Closed -$2K – 4229
2015
Q1 		$2K Hold
18
– – ﹤0.01% 3993
2014
Q4 		$3K Hold
18
– – ﹤0.01% 4018
2014
Q3 		$4K Buy
18
+5
+38% +$1.67K ﹤0.01% 3952
2014
Q2 		$6K Buy
+13
New +$6K ﹤0.01% 3832

Other funds holding IDXG

HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AA
Ancora Advisors Cleveland, Ohio $4.7B AUM 19.05% 1-Year Est. Return
LCM
Leonard Capital Management Vero Beach, Florida $5.25M AUM
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
PHS
Pekin Hardy Strauss Chicago, Illinois $1.14B AUM 37.36% 1-Year Est. Return
SKK
Shepherd Kaplan Krochuk Boston, Massachusetts $119M AUM 8.32% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $22.7B AUM

BlackRock Investment Management's IDXG Position: Q2 2015 in Review

BlackRock Investment Management sold out of Interpace Biosciences, Inc. Common Stock (IDXG) in Q2 2015, closing a stake of 18 shares — an estimated $2K sold.

BlackRock Investment Management first reported a position in IDXG in Q2 2014 and held it in 4 quarters. The position peaked at $6K in Q2 2014. 23 funds tracked by Wall St. Rank hold IDXG as of Q2 2015.

  • BlackRock Investment Management reported no remaining Interpace Biosciences, Inc. Common Stock position as of Q2 2015 after selling out during the quarter.
  • BlackRock Investment Management sold 18 Interpace Biosciences, Inc. Common Stock shares in Q2 2015, an estimated $2K.
  • BlackRock Investment Management first reported a position in Interpace Biosciences, Inc. Common Stock in Q2 2014 and held it in 4 quarters.
  • BlackRock Investment Management's Interpace Biosciences, Inc. Common Stock position peaked at $6K in Q2 2014.
  • 23 funds tracked by Wall St. Rank held Interpace Biosciences, Inc. Common Stock as of Q2 2015.

Based on BlackRock Investment Management's 13F filing for Q2 2015, filed 7 Aug 2015.